Differentially expressed messenger RNA/proteins can distinguish teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection tissue.
Tim NestlerLara KremerMelanie von BrandensteinMaike WittersheimPia PaffenholzSvenja Wagener-RyczekAlexander QuaasMartin HellmichStefan MüllerDavid PfisterMargarete OdenthalAxel HeidenreichPublished in: Cancer (2022)
The proteins and the corresponding genes called AGR2 and KRT19 can differentiate between teratoma and necrosis in remaining tumor masses after chemotherapy in patients who have metastasized testicular cancer. This may be a way to improve presurgical diagnostics and to reduce the current overtreatment of patients with necrosis only, who could be treated sufficiently by surveillance.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- public health
- chronic kidney disease
- peritoneal dialysis
- lymph node
- genome wide
- robot assisted
- prognostic factors
- prostate cancer
- gene expression
- patient reported outcomes
- squamous cell carcinoma
- computed tomography
- squamous cell
- locally advanced
- radiation therapy
- young adults
- minimally invasive
- childhood cancer
- contrast enhanced ultrasound